CRISPR-Based Gene Editing Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis 
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on CRISPR-Based Gene Editing Market

5.1. COVID-19 Landscape: CRISPR-Based Gene Editing Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers

Chapter 8. Global CRISPR-Based Gene Editing Market, By Product

8.1. CRISPR-Based Gene Editing Market, by Product
8.1.1. Kits and Reagents
8.1.1.1. Market Revenue and Forecast 
8.1.2. Services 
8.1.2.1. Market Revenue and Forecast

Chapter 9. Global CRISPR-Based Gene Editing Market, By Gene Editing Modality

9.1. CRISPR-Based Gene Editing Market, by Gene Editing Modality
9.1.1. Ex-Vivo Editing 
9.1.1.1. Market Revenue and Forecast 
9.1.2. In-Vivo Editing 
9.1.2.1. Market Revenue and Forecast

Chapter 10. Global CRISPR-Based Gene Editing Market, By Technology

10.1. CRISPR-Based Gene Editing Market, by Technology
10.1.1. CRISPR/Cas9 Technology 
10.1.1.1. Market Revenue and Forecast 
10.1.2. CRISPR/Cas12 Technology 
10.1.2.1. Market Revenue and Forecast 
10.1.3. CRISPR/Cas13 Technology 
10.1.3.1. Market Revenue and Forecast 
10.1.4. Base Editing 
10.1.4.1. Market Revenue and Forecast 
10.1.5. Prime Editing 
10.1.5.1. Market Revenue and Forecast 
10.1.6. Epigenetic Editing 
10.1.6.1. Market Revenue and Forecast 
10.1.7. Others
10.1.7.1. Market Revenue and Forecast

Chapter 11. Global CRISPR-Based Gene Editing Market, By Application

11.1. CRISPR-Based Gene Editing Market, by Application
11.1.1. Therapeutic Applications 
11.1.1.1. Market Revenue and Forecast 
11.1.2. Agriculture and Livestock 
11.1.2.1. Market Revenue and Forecast 
11.1.3. Industrial Biotechnology 
11.1.3.1. Market Revenue and Forecast

Chapter 12. Global CRISPR-Based Gene Editing Market, By End User

12.1. CRISPR-Based Gene Editing Market, by End User
12.1.1. Academic and Research Institutes 
12.1.1.1. Market Revenue and Forecast 
12.1.2. Biotechnology and Pharmaceutical Companies 
12.1.2.1. Market Revenue and Forecast 
12.1.3. Agricultural and Livestock Industry 
12.1.3.1. Market Revenue and Forecast 
12.1.4. Hospitals and Clinics 
12.1.4.1. Market Revenue and Forecast 
12.1.5. Contract Research Organizations (CROs)
12.1.5.1. Market Revenue and Forecast

Chapter 13. Global CRISPR-Based Gene Editing Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue and Forecast, by Product 
13.1.2. Market Revenue and Forecast, by Gene Editing Modality 
13.1.3. Market Revenue and Forecast, by Technology 
13.1.4. Market Revenue and Forecast, by Application 
13.1.5. Market Revenue and Forecast, by End User 
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product 
13.1.6.2. Market Revenue and Forecast, by Gene Editing Modality 
13.1.6.3. Market Revenue and Forecast, by Technology 
13.1.6.4. Market Revenue and Forecast, by Application 
13.1.6.5. Market Revenue and Forecast, by End User  
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product 
13.1.7.2. Market Revenue and Forecast, by Gene Editing Modality 
13.1.7.3. Market Revenue and Forecast, by Technology 
13.1.7.4. Market Revenue and Forecast, by Application 
13.1.7.5. Market Revenue and Forecast, by End User 
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product 
13.2.2. Market Revenue and Forecast, by Gene Editing Modality 
13.2.3. Market Revenue and Forecast, by Technology 
13.2.4. Market Revenue and Forecast, by Application  
13.2.5. Market Revenue and Forecast, by End User  
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product 
13.2.6.2. Market Revenue and Forecast, by Gene Editing Modality 
13.2.6.3. Market Revenue and Forecast, by Technology 
13.2.7. Market Revenue and Forecast, by Application  
13.2.8. Market Revenue and Forecast, by End User  
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product 
13.2.9.2. Market Revenue and Forecast, by Gene Editing Modality 
13.2.9.3. Market Revenue and Forecast, by Technology 
13.2.10. Market Revenue and Forecast, by Application 
13.2.11. Market Revenue and Forecast, by End User 
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product 
13.2.12.2. Market Revenue and Forecast, by Gene Editing Modality 
13.2.12.3. Market Revenue and Forecast, by Technology 
13.2.12.4. Market Revenue and Forecast, by Application 
13.2.13. Market Revenue and Forecast, by End User 
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product 
13.2.14.2. Market Revenue and Forecast, by Gene Editing Modality 
13.2.14.3. Market Revenue and Forecast, by Technology 
13.2.14.4. Market Revenue and Forecast, by Application 
13.2.15. Market Revenue and Forecast, by End User 
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product 
13.3.2. Market Revenue and Forecast, by Gene Editing Modality 
13.3.3. Market Revenue and Forecast, by Technology 
13.3.4. Market Revenue and Forecast, by Application 
13.3.5. Market Revenue and Forecast, by End User 
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product 
13.3.6.2. Market Revenue and Forecast, by Gene Editing Modality 
13.3.6.3. Market Revenue and Forecast, by Technology 
13.3.6.4. Market Revenue and Forecast, by Application 
13.3.7. Market Revenue and Forecast, by End User 
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product 
13.3.8.2. Market Revenue and Forecast, by Gene Editing Modality 
13.3.8.3. Market Revenue and Forecast, by Technology 
13.3.8.4. Market Revenue and Forecast, by Application 
13.3.9. Market Revenue and Forecast, by End User 
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product 
13.3.10.2. Market Revenue and Forecast, by Gene Editing Modality 
13.3.10.3. Market Revenue and Forecast, by Technology 
13.3.10.4. Market Revenue and Forecast, by Application 
13.3.10.5. Market Revenue and Forecast, by End User 
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product 
13.3.11.2. Market Revenue and Forecast, by Gene Editing Modality 
13.3.11.3. Market Revenue and Forecast, by Technology 
13.3.11.4. Market Revenue and Forecast, by Application 
13.3.11.5. Market Revenue and Forecast, by End User 
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product 
13.4.2. Market Revenue and Forecast, by Gene Editing Modality 
13.4.3. Market Revenue and Forecast, by Technology 
13.4.4. Market Revenue and Forecast, by Application 
13.4.5. Market Revenue and Forecast, by End User 
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product 
13.4.6.2. Market Revenue and Forecast, by Gene Editing Modality 
13.4.6.3. Market Revenue and Forecast, by Technology 
13.4.6.4. Market Revenue and Forecast, by Application 
13.4.7. Market Revenue and Forecast, by End User 
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product 
13.4.8.2. Market Revenue and Forecast, by Gene Editing Modality 
13.4.8.3. Market Revenue and Forecast, by Technology 
13.4.8.4. Market Revenue and Forecast, by Application 
13.4.9. Market Revenue and Forecast, by End User 
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product 
13.4.10.2. Market Revenue and Forecast, by Gene Editing Modality 
13.4.10.3. Market Revenue and Forecast, by Technology 
13.4.10.4. Market Revenue and Forecast, by Application 
13.4.10.5. Market Revenue and Forecast, by End User 
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product 
13.4.11.2. Market Revenue and Forecast, by Gene Editing Modality 
13.4.11.3. Market Revenue and Forecast, by Technology 
13.4.11.4. Market Revenue and Forecast, by Application 
13.4.11.5. Market Revenue and Forecast, by End User 
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product 
13.5.2. Market Revenue and Forecast, by Gene Editing Modality 
13.5.3. Market Revenue and Forecast, by Technology 
13.5.4. Market Revenue and Forecast, by Application 
13.5.5. Market Revenue and Forecast, by End User 
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product 
13.5.6.2. Market Revenue and Forecast, by Gene Editing Modality 
13.5.6.3. Market Revenue and Forecast, by Technology 
13.5.6.4. Market Revenue and Forecast, by Application 
13.5.7. Market Revenue and Forecast, by End User 
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product 
13.5.8.2. Market Revenue and Forecast, by Gene Editing Modality 
13.5.8.3. Market Revenue and Forecast, by Technology 
13.5.8.4. Market Revenue and Forecast, by Application 
13.5.8.5. Market Revenue and Forecast, by End User

Chapter 14. Company Profiles

14.1. CRISPR Therapeutics AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Agilent Technologies, Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Thermo Fisher Scientific, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. GeneCopoeia, Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Synthego Corporation
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. System Biosciences LLC
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. ToolGen, Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Rockland Immunochemicals, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Horizon Discovery Group PLC
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Abcam, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions

Chapter 16. Appendix

16.1. About Us
16.2. Glossary of Terms